The Department of Justice secured an agreement forcing Connecticut Children's Medical Center to end pediatric gender-related drug treatments, pay a financial penalty, and fund $500,000 in care for those allegedly harmed, the third such deal the DOJ has reached with a major hospital.
Associate Attorney General Stanley Woodward announced the agreement Wednesday, calling it part of an ongoing federal investigation into potential violations of law connected to the administration of sex-change drugs and surgeries on minors. Connecticut Children's is the latest institution to reach terms with the DOJ, following earlier agreements with Texas Children's Hospital and the Cleveland Clinic Foundation.
Under the deal, Connecticut Children's agreed to three conditions: it will stop administering gender-related drugs to minors, it will pay a monetary penalty whose precise amount was not disclosed, and it will dedicate $500,000 in medical care for individuals the DOJ alleges were harmed by the treatments. The DOJ noted that the agreements are based on allegations only and that Connecticut Children's has denied all allegations.
Woodward's statement left no ambiguity about the Justice Department's posture toward medical providers still offering these treatments to children. Breitbart News reported his full remarks Wednesday:
"The Department of Justice will stop at nothing to protect America's children. This resolution is a reminder to hospitals, medical providers, and pharmaceutical companies that the Justice Department will vigorously enforce federal law, especially where the lives of children are endangered."
That language, directed not just at hospitals but at pharmaceutical companies, signals the DOJ views this as a broader enforcement campaign, not a series of one-off settlements. Three major medical institutions have now signed similar agreements. The specific federal statutes the DOJ believes were violated have not been publicly identified in the announcement.
Brett Shumate, the assistant attorney general for the Civil Division, reinforced that message. He named all three institutions by name and framed the agreements as a floor, not a ceiling, for the department's enforcement effort. The Trump administration has made protecting children from gender-related medical interventions a visible policy priority, and the DOJ's language reflects that commitment.
Shumate stated:
"As with Texas Children's and Cleveland Clinic before it, I am encouraged when leading institutions like Connecticut Children's agree to be part of the solution and no longer the problem. But while we can be grateful when we arrive at such positive resolutions, we cannot and will not rest in our pursuit of justice for the victims of these discredited practices."
His use of "discredited practices" is notable. It puts the DOJ on record characterizing pediatric gender-related drug treatments not as a contested medical question but as a settled one, settled against the providers.
The hospital's public response, delivered through the Hartford Courant, struck a careful tone. Connecticut Children's denied all allegations but emphasized its cooperation with the federal investigation and its commitment to patient privacy.
"Most importantly, patient privacy remained our foremost concern throughout this process and we were able to resolve this matter without disclosing any protected patient information to the US government. We have complied and will continue to comply with all federal and state laws. We have no additional comment beyond the information contained in today's DOJ announcement."
The hospital also said the agreement "allows our organization to remain focused on our mission of improving the health and well-being of children." That framing positions the deal as a practical resolution rather than an admission of fault. But the terms themselves, ceasing the treatments, paying a penalty, and funding half a million dollars in restorative care, carry their own weight regardless of how the hospital characterizes them.
The DOJ acknowledged that Connecticut Children's "took significant steps entitling it to credit for cooperation" and described the medical center as having "remained cooperative, proactive, and solution-driven" throughout the investigation. That cooperation may explain why the institution's name appears alongside a settlement rather than a lawsuit. The Trump administration has shown it can pursue aggressive legal strategies when institutions resist, cooperation appears to have earned Connecticut Children's a different outcome.
The Connecticut Children's agreement marks the third time the DOJ has secured this type of deal with a major medical institution. Texas Children's Hospital and the Cleveland Clinic Foundation both reached similar arrangements earlier, though the specific dates and terms of those prior agreements were not detailed in the DOJ's Wednesday announcement.
The pattern is clear. The DOJ is moving institution by institution, using federal enforcement authority to shut down pediatric gender-related drug programs at hospitals that had been providing them. Shumate's statement that the department "cannot and will not rest" suggests more agreements, or, if institutions refuse to cooperate, more confrontational enforcement actions, are coming.
Several questions remain unanswered. The DOJ has not publicly identified which federal laws it believes these hospitals violated. The number of minors allegedly affected and the time period over which the treatments occurred have not been disclosed. The specific treatments covered by the agreement, whether puberty blockers, cross-sex hormones, or both, were not broken out in the announcement. And the precise dollar amount of the monetary penalty, separate from the $500,000 restorative care commitment, remains undisclosed.
What is disclosed is enough to draw the outline. A federal investigation found enough to bring a major children's hospital to the table. That hospital agreed to stop the treatments, pay money, and fund care for those allegedly harmed. It denied wrongdoing but signed anyway. The administration's broader political agenda, including its willingness to confront institutions and media narratives head-on, provides the backdrop for these enforcement actions.
The $500,000 restorative care fund is itself a pointed detail. It presumes that individuals who received these treatments may need medical help to address the consequences. The mechanism for distributing that care has not been explained, but the existence of the fund tells you what the DOJ thinks happened to the patients.
For years, critics warned that administering powerful hormonal drugs to minors carried serious risks and that the medical establishment was moving too fast, driven more by ideology than by evidence. Those critics were dismissed, mocked, and in some cases professionally punished. Now the Justice Department of the United States is securing agreements that treat those same practices as potential violations of federal law.
Three hospitals have signed. The DOJ says more are coming. The institutions that spent years insisting these treatments were safe, necessary, and compassionate now find themselves choosing between cooperation and confrontation with federal investigators. That shift did not happen by accident. It happened because voters demanded accountability, and an administration delivered it.